
Bayer (XTRA:BAYN) has received U.S. FDA approval for SUNHARBO, a first in class Factor XIa inhibitor for reducing stroke risk after recent non cardioembolic ischemic stroke or high risk transient ischemic attack.
Bayer's latest SUNHARBO approval lands after a strong run in the market, with the latest share price at €57.0 and a 30 day share price return of 28.21% and year to date share price return of 50.00%. The 1 year total shareholder return of 104.56% suggests momentum has been building alongside recent product wins and improving reported profitability.
Scan other pharma and biotech movers showing similar momentum to Bayer using our hand picked 211 high quality undervalued stocks.
Bayer has already doubled shareholder returns over the past year, yet SUNHARBO’s approval has only just hit the tape. Is most of the share price reset already done, or is the valuation still playing catch up?
Bayer’s last close at €57.0 sits just below the analyst consensus Narrative fair value of €58.22, which frames SUNHARBO’s approval inside a broader turnaround plan shaped by Crop Science restructuring, litigation management and a refreshed pharma pipeline. According to the analyst consensus Narrative on Simply Wall St, that mix of execution goals, earnings forecasts and a 5.5% discount rate underpins the small implied undervaluation.
The main thing that has to go right is that Bayer converts its Crop Science and pharma programs, including the 2024 to 2029 efficiency framework and the AI and data driven R&D engine, into higher quality earnings and sustained free cash flow while containing litigation and capital spending pressures.
The current valuation implies that the market is discounting Bayer’s progress on margin improvement, litigation containment and balance sheet repair, and that the stock is pricing in a weaker outlook than this bullish, undervalued narrative describes.
See why 164 investors see Bayer as 2% undervalued.
Result: Fair Value of €58.22 (UNDERVALUED)
Still, Bayer’s heavy litigation cash outflows and the complex Crop Science restructuring could easily derail that upbeat earnings and valuation narrative.
Find out about the key risks to this Bayer narrative.
Analyst narratives point to Bayer trading a touch below a €58.22 fair value, yet the Simply Wall St DCF model paints a very different picture. On that cash flow lens, the current share price of €57.0 sits far above an estimated value of €4.32, which raises a sharp question: Is the market leaning too heavily on earnings forecasts and not enough on long term cash generation?
For a closer look at how that gap is built up by assumptions on cash flows, growth and discount rates, take a moment to walk through the full model output here, then decide which framework feels more realistic for you: the market implied view or the cash flow driven result from the SWS DCF model, Look into how the SWS DCF model arrives at its fair value..
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Bayer for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 211 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
If this mix of optimism and caution around Bayer feels finely balanced, use the data to pressure test it yourself and decide where you stand, starting with the 2 key rewards.
If Bayer has you rethinking what is possible in your portfolio, do not stop at a single ticker. Broader idea flow often leads to better decisions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com